<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00958906</url>
  </required_header>
  <id_info>
    <org_study_id>GCO # 09-0611</org_study_id>
    <nct_id>NCT00958906</nct_id>
  </id_info>
  <brief_title>Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema</brief_title>
  <official_title>Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if intravitreal infliximab is a safe and effective&#xD;
      treatment for macular edema secondary to uveitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with uveitic macular edema will be treated with one injection of intravitreal&#xD;
      infliximab (2.0mg/0.05ml) and followed for three months. Outcomes that be assessed include&#xD;
      best-corrected visual acuity, macular thickness as measured by optical coherence tomography,&#xD;
      and electroretinogram responses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI left institution (there are no data results for this study)&#xD;
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best-corrected visual acuity</measure>
    <time_frame>Three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Macular thickness</measure>
    <time_frame>One, two, and three months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Uveitic Macular Edema</condition>
  <condition>Intraocular Inflammation</condition>
  <arm_group>
    <arm_group_label>Intravitreal infliximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab (intravitreal, 2.0mg/0.05ml)</intervention_name>
    <description>One injection of intravitreal infliximab (2.0mg/0.05ml).</description>
    <arm_group_label>Intravitreal infliximab</arm_group_label>
    <other_name>Remicade™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant must be 18 years of age or older.&#xD;
&#xD;
          2. Participant must understand and sign the protocol's informed consent document.&#xD;
&#xD;
          3. Participants must have uveitic macular edema in one eye as defined by all of the&#xD;
             following criteria:&#xD;
&#xD;
               1. Presence of active intermediate uveitis or posterior uveitis.&#xD;
&#xD;
               2. Macular edema defined as a central macular thickness of ≥ 250 μm on OCT.&#xD;
&#xD;
               3. Uveitis must be noninfectious as determined by standard investigations used in&#xD;
                  the diagnostic investigation of uveitis.&#xD;
&#xD;
          4. Participant must have visual acuity between 20/40 and hand motions in the study eye.&#xD;
&#xD;
          5. Participant must have a steady fixation in the study eye and media clear enough for&#xD;
             good quality imaging.&#xD;
&#xD;
          6. Female participants of childbearing potential must not be pregnant or breast-feeding,&#xD;
             must have a negative pregnancy test at screening and must practice an adequate method&#xD;
             of birth control. Males able to father a child must agree to practice birth control.&#xD;
             Acceptable methods of birth control include hormonal contraception (birth control&#xD;
             pills, injected hormones or vaginal ring), intrauterine device, barrier methods with&#xD;
             spermicide (diaphragm with spermicide, condom and spermicide) or surgical&#xD;
             sterilization (hysterectomy, tubal ligation or vasectomy in a partner). If a&#xD;
             participant is of childbearing potential, she must be willing to undergo monthly urine&#xD;
             pregnancy tests. Both males and females must agree to use adequate birth control for&#xD;
             three months after the intravitreal infliximab injection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participant is in another investigational study and actively receiving study therapy.&#xD;
&#xD;
          2. Participant is unable to comply with study procedures or follow-up visits.&#xD;
&#xD;
          3. Participant has uveitic macular edema (as defined above) in both eyes.&#xD;
&#xD;
          4. Participant has multiple sclerosis or symptoms suggestive of multiple sclerosis.&#xD;
&#xD;
          5. Participant has evidence of ocular disease other than uveitis in either eye that may&#xD;
             confound the outcome of the study (e.g., diabetic retinopathy, age-related macular&#xD;
             degeneration, vitreomacular traction, moderate/severe myopia, etc.).&#xD;
&#xD;
          6. Participant is expected to need ocular surgery in the study eye during the course of&#xD;
             the study.&#xD;
&#xD;
          7. Participant has undergone ocular surgery or an intravitreal/periocular steroid&#xD;
             injection in the study eye within the past 3 months.&#xD;
&#xD;
          8. Participant has had a YAG laser capsulotomy or intravitreal anti-VEGF treatment in the&#xD;
             study eye within the past 6 weeks.&#xD;
&#xD;
          9. Participant has had a pars plana vitrectomy in the study eye.&#xD;
&#xD;
         10. Participant is on ocular or systemic medications known to be toxic to the lens,&#xD;
             retina, or optic nerve.&#xD;
&#xD;
         11. Participant with a history of ocular herpes simplex virus infection in the study eye.&#xD;
&#xD;
         12. A condition that, in the opinion of the investigator, would preclude participation in&#xD;
             the study (e.g., unstable medical status including blood pressure and glycemic&#xD;
             control).&#xD;
&#xD;
         13. There are no criteria for inclusion/exclusion for the fellow eye. Only one eye can&#xD;
             have macular edema in order for the potential participant to be considered for&#xD;
             enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farzin Forooghian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology, Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol. 2009 May;147(5):825-30, 830.e1. doi: 10.1016/j.ajo.2008.12.004. Epub 2009 Feb 10.</citation>
    <PMID>19211094</PMID>
  </reference>
  <reference>
    <citation>Theodossiadis PG, Liarakos VS, Sfikakis PP, Charonis A, Agrogiannis G, Kavantzas N, Vergados IA. Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit. Graefes Arch Clin Exp Ophthalmol. 2009 Feb;247(2):273-81. doi: 10.1007/s00417-008-0967-4. Epub 2008 Nov 4.</citation>
    <PMID>18982345</PMID>
  </reference>
  <reference>
    <citation>Giansanti F, Ramazzotti M, Vannozzi L, Rapizzi E, Fiore T, Iaccheri B, Degl' Innocenti D, Moncini D, Menchini U. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1151-6. doi: 10.1167/iovs.07-0932.</citation>
    <PMID>18326743</PMID>
  </reference>
  <reference>
    <citation>Olson JL, Courtney RJ, Mandava N. Intravitreal infliximab and choroidal neovascularization in an animal model. Arch Ophthalmol. 2007 Sep;125(9):1221-4.</citation>
    <PMID>17846362</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>August 11, 2009</study_first_submitted>
  <study_first_submitted_qc>August 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2009</study_first_posted>
  <last_update_submitted>June 21, 2011</last_update_submitted>
  <last_update_submitted_qc>June 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Farzin Forooghian, MD, Assistant Professor</name_title>
    <organization>Department of Ophthalmology, Mount Sinai School of Medicine</organization>
  </responsible_party>
  <keyword>Infliximab</keyword>
  <keyword>Uveitis</keyword>
  <keyword>Macular Edema</keyword>
  <keyword>Intraocular Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

